Company News for November 17, 2010 - Corporate Summary

• Target's TGT third quarter matched sales and earnings estimates, with earnings of $0.68 and revenues $15.61 billion

• BJ's Wholesale Club BJ posed third quarter results beating estimates by $0.07 at $0.43, on revenues up 4.9% YoY to $2.6 billion, in-line with expectations

• Human Genome Sciences HGSI resumed trading this morning after news that its lupus-fighting drug, Benlysta, developed with GlaxoSmithKline GSK, was recommended for FDA approval by an FDA advisory panel. Even so, two firms downgraded Human Genome shares

• Potash POT, recently successful in fighting off BHP Billiton's BHP takeover bid, initiated a $2 billion, one-year share buyback program

• Goldman Sachs GS downgraded Norfolk Southern NSC from "neutral" to "sell," taking its price target from $62 to $59

• FBR maintained its "outperform" rating on Marvell MRVL, with a price target of $25

• Jefferies JEF maintained a "buy" on Home Depot HD, with a price target of $36

• Goldman Sachs GS upgraded CSX CSX from "sell" to "neutral," lifting its price target from $60 to $63

 
BHP BILLITN LTD (BHP): Free Stock Analysis Report
 
BJ'S WHOLESALE (BJ): Free Stock Analysis Report
 
CSX CORP (CSX): Free Stock Analysis Report
 
GOLDMAN SACHS (GS): Free Stock Analysis Report
 
HOME DEPOT (HD): Free Stock Analysis Report
 
HUMAN GENOME (HGSI): Free Stock Analysis Report
 
JEFFERIES GP-NW (JEF): Free Stock Analysis Report
 
MARVELL TECH GP (MRVL): Free Stock Analysis Report
 
NORFOLK SOUTHRN (NSC): Free Stock Analysis Report
 
POTASH SASK (POT): Free Stock Analysis Report
 
TARGET CORP (TGT): Free Stock Analysis Report
 
Zacks Investment Research